Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind ( MNKD ) Reports Break-Even Earnings for Q2
MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. ( KRYS ) Tops Q2 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
FLORHAM PARK, N.J., July 28, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on ...
Agios Pharmaceuticals ( AGIO ) Moves 7.7% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
FLORHAM PARK, N.J., June 23, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that, in connection with the appointment of Anne ...
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® ( vonoprazan ) Tablets Through May 3, 2032 - Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., June 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that the U.S.
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® ( vonoprazan ) Tablets Through May 3, 2032
FLORHAM PARK, N.J., June 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that the U.S.
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Bunge Global ( NYSE:BG ) , AleAnna ( NASDAQ:ANNA )
U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday. Shares of Unusual Machines, Inc. UMAC rose sharply during Friday's session after the company agreed to acquire Rotor Lab in all-stock deal valued at $7 million.
Wall Street Analysts Believe Phathom Pharmaceuticals ( PHAT ) Could Rally 107.4%: Here's is How to Trade
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna - Phathom Pharmaceuticals ( NASDAQ:PHAT )
Phathom Pharmaceuticals shares are up over 100% after the FDA granted 10-year market exclusivity for Voquezna through 2032. The FDA updated its Orange Book to reflect full NCE+GAIN exclusivity, blocking generics and boosting Phathom's long-term revenue potential.
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® ( vonoprazan ) Tablets through May 3, 2032 - Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., June 06, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT today announced that the U.S.
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® ( vonoprazan ) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the ...
Palo Alto Networks, Take-Two Interactive Software, VF Corp And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Akso Health ( NASDAQ:AHG ) , Archer Aviation ( NYSE:ACHR )
U.S. stock futures were lower this morning, with the Dow futures falling around 400 points on Wednesday. Shares of Palo Alto Networks, Inc. PANW fell in pre-market trading following quarterly results. Palo Alto reported third-quarter revenue of $2.29 billion, beating the consensus estimate of ...
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations
Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at ...
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals ( PHAT )
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in ...
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
FLORHAM PARK, N.J., May 01, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that, in connection with the appointment of ...
Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -0.94% and 1.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
FLORHAM PARK, N.J., May 01, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today reported financial results for the first quarter ended March ...
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May ...
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors - Cidara Therapeutics ( NASDAQ:CDTX ) , Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., April 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
FLORHAM PARK, N.J., April 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of ...
Rhythm Pharmaceuticals ( RYTM ) Surges 17.1%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of the management team will ...
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., April 03, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of the management team will ...
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
FLORHAM PARK, N.J., April 01, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that, in connection with the appointment of ...
Phathom Pharmaceuticals Announces Leadership Succession - Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., April 01, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that Steven Basta has been appointed President and Chief ...
Phathom Pharmaceuticals Announces Leadership Succession
FLORHAM PARK, N.J., April 01, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that Steven Basta has been appointed President ...
Phathom Pharmaceuticals Announces Leadership Succession
FLORHAM PARK, N.J., April 01, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that Steven Basta has been appointed President ...
IHS Holding Posts Upbeat Earnings, Joins Tencent Music Entertainment, Elbit Systems And Other Big Stocks Moving Higher On Tuesday - Diginex ( NASDAQ:DGNX ) , China Liberal Education ( NASDAQ:CLEU )
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Tuesday. Shares of IHS Holding Limited IHS rose sharply during Tuesday's session following fourth-quarter results. IHS Holding reported quarterly earnings of 73 cents per share which beat the analyst consensus estimate ...
Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q4 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 19.39% and 17.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Phathom Pharmaceuticals ( NASDAQ:PHAT )
VOQUEZNA® ( vonoprazan ) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3 Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since ...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., March 06, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today reported financial results for the fourth quarter and full ...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - Phathom Pharmaceuticals ( NASDAQ:PHAT )
Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
FLORHAM PARK, N.J., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on ...
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
FLORHAM PARK, N.J., Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of the management team will ...
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® ( vonoprazan ) Tablets
FLORHAM PARK, N.J., Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today it has submitted a Citizen Petition ( CP ) with ...
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals ( PHAT ) Looks Ripe for a Turnaround
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Phathom Pharmaceuticals ( PHAT ) Upgraded to Buy: Here's What You Should Know
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 15.92% and 30.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of its management team are scheduled ...
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
FLORHAM PARK, N.J., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on ...
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology ( ACG ) 2024 Annual Meeting - Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., Oct. 27, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology ( ACG ) 2024 Annual Meeting
FLORHAM PARK, N.J., Oct. 27, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that the company will present data from multiple ...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of its management team are scheduled to participate ...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, announced today that members of its management team are scheduled ...
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 ...
Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -4.17% and 29.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today reported financial results for the second quarter of 2024, ...
